CRISPR Therapeutics AG (NASDAQ: CRSP ) is one of them ARK Investment Stock Portfolio: Top 10 Stock Picks for 2026, With a share value of over $551 million by Q4 2025.
The gene editing company remains on the radar of analysts and currently has a moderate buy rating, with an average share price upside of 17% as of March 4.
Recent updates include Trust Financial analyst Jon Lee reiterating the company’s buy rating on the stock on March 2, according to Tepanix.
Earlier on February 17, Chardan Capital raised its price target on CRISPR Therapeutics AG (NASDAQ: CRSP ) from $74 to $76 and maintained a buy rating. The revision followed the company’s business update and announcement of its fourth quarter results on February 12.
Jirsak/Shutterstock.com
According to TipRanks, Chardonnay analyst Jeola Liushets highlighted the company’s siRNA therapeutics and in vivo cardiac editing movement with progress in several clinical and preclinical programs.
Following the Q4 report, TD Cowen raised its price target to $45 from $40 with a hold rating. The company noted strong momentum in CASGEVY, with quarterly revenue of $54 million and full-year revenue of $116 million. Additionally, analyst Taylor Van Buren said he expects several clinical updates scheduled for the second half of 2026.
CRISPR Therapeutics AG (NASDAQ: CRSP ) is a gene editing company focused on developing CRISPR/Cas9-based therapies to treat genetically defined diseases and engineer advanced cellular therapies.
While we acknowledge CRSP’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 10 Best Magic Formula Stocks for 2026.
Disclosure: None. Follow the inside port on Google News.
